Tumour-targeted delivery of therapeutic nanoparticles
Nanocapture is a translational biomedical research project. Our small pre-seed team is based at the Pharmacy Department at the Ludwig-Maximilians-Universität Munich, Germany. Supported by the GO-Bio program of the German Federal Government – BMBF, our team is aiming to significantly improve the selectivity of drug delivery during tumour chemotherapies. In our key proof-of concept studies, we could demonstrate that our lead product, NanoCap-DLV, effectively slows down tumour progression in aggressive models of pancreatic and breast cancer compared to the standard of care.
The NanoCapture is a multidisciplinary team with experts in chemistry, in vivo biology and oncology.
DR. PETAR MARINKOVIĆ
Petar brings more than 10 years of experience in leading scientific projects. Together with Dr. Thorn-Seshold, he performed first proof-of-principle studies and obtained the initial funding for the project. He is responsible for the overall project strategy, as well as for the scientific and business development.
DR. JULIA AHLFELD
Translational research scientist
Julia is a scientist with a strong background in tumour pathology, neurobiology and molecular biology. In addition, she brings valuable experience in conducting and organizing clinical trials. Within the NanoCapture project, she is responsible for the in-house studies and data analysis.
DR. OLIVER THORN-SESHOLD
ASSOCIATED MEMBER - ADVISOR
Oliver is the inventor of the NanoCapture concept which won the 2015 Innovationsakademie competition. With the strong background in medicinal chemistry, his main research interest is developing more selective and powerful anticancer drugs. Oliver is a junior group leader at the Pharmacy Department at LMU and remains a close advisor to the NanoCapture project.